CD19 and B-cell non-Hodgkin lymphoma: For the 3 established CD19-directed CAR therapies with FDA approval for aggressive B-cell lymphomas in the third-line setting (tisagenlecleucel, axicabtagene ciloleucel, and lisocabtagene maraleucel), RCTs comparing these therapies with SOC therapy in the second-line setting are being conducted through the BELINDA study,16 ZUMA-7 study,14 and the TRANSFORM phase 3 study.17 Equipoise between CAR-T therapy and SOC chemotherapies certainly is more feasible here than in the third-line setting for patients with chemorefractory disease.